About Affinity Biosensors
Affinity Biosensors is a Healthcare company based in Santa Barbara (United States) founded in 2006. It operates as a rapid antimicrobial susceptibility testing devices are developed for life sciences. Affinity Biosensors has raised $51.8 million across 16 funding rounds from investors including National Science Foundation. The company has 21 employees. Its chief executive is Ken Babcock. Affinity Biosensors offers products and services including LifeScale AST System. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is AFFINITY BIOSENSORS, LLC. Its competitors include Prenetics, OpGen, Day Zero Diagnostics, Clear Labs and Karius and 4 more; 8 of its 9 listed competitors have raised funding.
Company details
Affinity Biosensors was founded in 2006 in Santa Barbara, United States. Devices for rapid antimicrobial susceptibility testing are developed by the company within the life sciences sector. LifeScale technology is provided, enabling population-profiling of Gram-negative bacteria from positive blood cultures. Additional offerings include primary and secondary antibodies, peptides, reagent kits, inhibitors, and related products for research and diagnostic applications.
- Headquarters Santa Barbara, United States
- Employees 21
- SectorsHealthcare
- Website affinitybio.com
- Social LinkedIn
- Legal Name Affinity Biosensors, Llc
- Total Equity Funding$51.8M (USD)
in 16 rounds
- Latest Funding Round$1.59M (USD), Post-IPO
Mar 2026
- Investors
- Employee Count21
Products & Services of Affinity Biosensors
Affinity Biosensors offers a comprehensive portfolio of products and services, including LifeScale AST System.
Provides rapid testing for bacterial resistance to antimicrobials.
Funding Insights of Affinity Biosensors
Affinity Biosensors has successfully raised a total of $51.8M across 16 strategic funding rounds. The most recent funding activity was a Post-IPO round of $1.59 million completed in March 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $51.8M
- Total Rounds 16
- Last Round Post-IPO — $1.59M
- First Round $746,845
(Jul 2007)
- Investors Count 1
Latest 10 of 16 funding rounds of Affinity Biosensors with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2026 | $1.59M | Post-IPO | – | – | – |
| Nov 2024 | $14.4M | Series B | – | – | – |
| Jun 2024 | $3.73M | Series A | – | – | – |
| Nov 2023 | $2.42M | Series A | – | – | – |
| Dec 2022 | $2.57M | Series A | – | – | – |
| Nov 2020 | $4.27M | Series A | – | – | – |
| Aug 2019 | $6.06M | Series A | – | – | – |
| Nov 2017 | $5.49M | Series A | – | – | – |
| Aug 2016 | $7.08M | Series A | – | – | – |
| Feb 2015 | $3M | Series A | – | – | – |
1 investors in total: 1 institutional.
Investors in Affinity Biosensors
Affinity Biosensors has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include National Science Foundation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
A government-backed foundation providing seed-stage investments to support small businesses. | 1950 | nsf.gov | Arlington, United States |
Investor details for Affinity Biosensors
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Affinity Biosensors
6 people are tracked at Affinity Biosensors (5 in leadership, 1 in team); the tracked headcount is 21.
| Name | Role | Group |
|---|---|---|
Ken Babcock | CEO | Leadership |
Webb Mechling | Director Of Business Development | Leadership |
Heather Nutting | Director, Clinical Laboratory Implementation Services | Leadership |
Steve Markakis | Chief Operating Officer | Leadership |
Nate Koenig | Chief Commercial Officer (cco) | Leadership |
Ragheed Z. Idrees | Field Services Engineer | Team |
Complete people profiles for Affinity Biosensors
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Affinity Biosensors
3 dated milestones of Affinity Biosensors across 20 years, from founding to its latest funding, stage changes and deals.
- Founded Affinity Biosensors is founded.
- Funding First funding round of $747K.
- Funding Latest funding round, Post-IPO, of $1.6M.
Competitors of Affinity Biosensors
Affinity Biosensors has 9 listed competitors in our database, 8 of them funded. They include Prenetics, OpGen, Day Zero Diagnostics, Clear Labs and Karius, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| prenetics.com | 2009 | Hong Kong, China | $67.65M | – | Health risks are identified through online genetic and diagnostic testing. | |
| opgen.com | 2002 | Rockville, United States | $77.51M | 100 | Developer of diagnostics and bioinformatics platforms for providers | |
| dayzerodiagnostics.com | 2016 | Boston, United States | $48.6M | 48 | Genome sequencing diagnostics for infectious diseases are developed. | |
| clearlabs.com | 2014 | Menlo Park, United States | $171.09M | 55 | Food safety technologies are provided for pathogen identification. | |
| kariusdx.com | 2014 | Redwood, United States | $315M | 139 | Developer of a non-invasive pathogen blood test for the detection of infectious diseases | |
| availsmedical.com | 2013 | Menlo Park, United States | $8.66M | – | Point-of-care devices are developed for infection diagnosis and treatment optimization. | |
| curetis.com | 2007 | Holzgerlingen, Germany | $127.14M | 55 | Molecular diagnostics platform is provided for infectious disease detection. | |
| seegene.com | 2000 | Seoul, South Korea | – | – | Developer of molecular diagnostic kits to detect infectious and genetic diseases | |
| nowdx.com | 2013 | Bentonville, United States | $65.69M | 28 | Develops rapid assay medical tests that use a single drop of blood to test for a variety of common conditions, illnesses and diseases |
Detailed competitors of Affinity Biosensors
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Affinity Biosensors
The website of Affinity Biosensors (affinitybio.com) receives about 1.3K visits a month.
- Monthly visits1.3K
▼ 21.1% vs previous month
Top companies in Genomics & Gene Therapy Platforms
10 companies that operate in the same segment as Affinity Biosensors (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 562 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Affinity Biosensors
Complete news archive for Affinity Biosensors
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Affinity Biosensors
Affinity Biosensors was founded in 2006 and raised its 1st funding round 1 year after it was founded.
Affinity Biosensors is headquartered in Santa Barbara, United States. It is registered at Santa Barbara, California, United States.
Ken Babcock is the current CEO of Affinity Biosensors.
Affinity Biosensors is a funded company, having raised a total of $51.8M across 16 funding rounds to date. The company's 1st funding round was a Series A of $3M, raised on Jul 2007.
Affinity Biosensors has 21 employees.
Affinity Biosensors was founded in 2006 in Santa Barbara, United States. Devices for rapid antimicrobial susceptibility testing are developed by the company within the life sciences sector. LifeScale technology is provided, enabling population-profiling of Gram-negative bacteria from positive blood cultures. Additional offerings include primary and secondary antibodies, peptides, reagent kits, inhibitors, and related products for research and diagnostic applications.
Affinity Biosensors's top competitors include Prenetics, Clear Labs and Day Zero Diagnostics.
Affinity Biosensors offers LifeScale AST System.
Affinity Biosensors has 1 investor. Key investors include National Science Foundation.
Affinity Biosensors operates through Affinity Biosensors, Llc.